Cyclerion Therapeutics (CYCN) Interest & Investment Income (2019 - 2020)
Cyclerion Therapeutics (CYCN) posted quarterly Interest & Investment Income of -$4000.0 for Q4 2020, down 100.75% year-over-year from $531000.0 in Q1 2020, and down 104.3% quarter-over-quarter from $93000.0 in Q3 2020.
Cyclerion Therapeutics (CYCN) Interest & Investment Income (2019 - 2020) Analysis & Trends
Cyclerion Therapeutics' Interest & Investment Income history runs 2 years deep, the most recent figure standing at -$4000.0 for Q4 2020.
- In Q4 2020, Interest & Investment Income fell 100.75% year-over-year to -$4000.0; the TTM figure through Dec 2020 stood at $588000.0 (changed N/A YoY), while the FY2020 annual figure was $588000.0, down 71.02% from the prior year.
- Interest & Investment Income for Q4 2020 stood at -$4000.0, down from $93000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $800000.0 in Q2 2019, with the low at -$4000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -4,000.00 |
| Sep 30, 2020 | 93,000.00 |
| Jun 30, 2020 | 138,000.00 |
| Mar 31, 2020 | 361,000.00 |
| Dec 31, 2019 | 531,000.00 |
| Sep 30, 2019 | 699,000.00 |
| Jun 30, 2019 | 800,000.00 |